ATI RN
ATI Pharmacology Proctored Exam 2019
1. A male client recently started taking Haloperidol. Which of the following findings is the highest priority to report to the provider?
- A. Shuffling gait
- B. Neck spasms
- C. Drowsiness
- D. Impotence
Correct answer: B
Rationale: Neck spasms are an indication of acute dystonia, a serious side effect of Haloperidol that can quickly progress to a crisis situation. Immediate medical attention is necessary to prevent complications. Shuffling gait and drowsiness are common side effects of Haloperidol but are not as urgent as neck spasms. Impotence is not typically associated with Haloperidol use. Therefore, identifying neck spasms as the priority finding is crucial for the client's safety.
2. A nurse is providing teaching to a client who has asthma and is beginning to take montelukast. Which of the following statements by the client indicates an understanding of the teaching?
- A. I will use this medication as a rescue inhaler during asthma attacks.
- B. I should take this medication once daily in the evening.
- C. I need to have my blood levels checked regularly while taking this medication.
- D. I should take this medication before exercising to prevent bronchospasm.
Correct answer: B
Rationale: Montelukast is typically taken once daily in the evening for long-term control of asthma symptoms. It helps prevent asthma attacks by reducing inflammation in the airways. While montelukast can also be used for exercise-induced bronchospasm in some cases, it is generally not a rescue medication and should be taken regularly, not on an as-needed basis.
3. A client is prescribed Digoxin. Which of the following findings should the nurse monitor as a sign of potential toxicity?
- A. Bradycardia
- B. Hypertension
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Corrected Rationale: Bradycardia is a common sign of Digoxin toxicity. Digoxin, a medication used to treat heart conditions, can lead to toxicity manifesting as bradycardia. Monitoring the client's heart rate closely is crucial to detect potential toxicity early and prevent complications. Hypertension, hyperglycemia, and hypocalcemia are not typically associated with Digoxin toxicity. Therefore, options B, C, and D are incorrect.
4. When administering Lithium to a patient, what is a life-threatening side effect?
- A. Erythema
- B. Pancreatitis
- C. Seizures
- D. Headache
Correct answer: C
Rationale: When a patient is being treated with Lithium, a life-threatening side effect to watch out for is seizures. Lithium can lower the seizure threshold, increasing the risk of seizures. Seizures are serious and necessitate prompt medical intervention to ensure the patient's safety and well-being. Erythema, which is redness of the skin, is not a common life-threatening side effect of Lithium. Pancreatitis can be a side effect of Lithium, but it is not typically life-threatening. Headache is a common side effect of Lithium, but it is not considered life-threatening.
5. A client has a new prescription for Hydralazine. Which of the following side effects should the nurse instruct the client to monitor for and report?
- A. Orthostatic hypotension
- B. Increased heart rate
- C. Dark-colored urine
- D. Persistent cough
Correct answer: B
Rationale: Corrected Rationale: Hydralazine, a vasodilator, can cause reflex tachycardia, leading to an increased heart rate. This side effect should be reported to the healthcare provider to ensure appropriate management and monitoring of the client's condition. Choice A (Orthostatic hypotension) is incorrect as Hydralazine is more likely to cause reflex tachycardia than orthostatic hypotension. Choice C (Dark-colored urine) and Choice D (Persistent cough) are unrelated to the common side effects of Hydralazine and should not be the focus of monitoring for this medication.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access